Holen Sie sich die Stockscreener-App
10.65
17.81%
1.61
Handel nachbörslich:
10.65
Schlusskurs vom Vortag:
$9.04
Offen:
$9.04
24-Stunden-Volumen:
9.57M
Relative Volume:
3.21
Marktkapitalisierung:
$663.41M
Einnahmen:
$16.10M
Nettoeinkommen (Verlust:
$-198.97M
KGV:
-3.0596
EPS:
-3.4809
Netto-Cashflow:
$-183.99M
1W Leistung:
-37.77%
1M Leistung:
-56.57%
6M Leistung:
-40.67%
1J Leistung:
-11.91%
1-Tages-Spanne:
$8.97
$11.33
1-Wochen-Bereich:
$8.73
$17.28
52-Wochen-Spanne:
$7.76
$71.50
Uniqure N V Stock (QURE) Company Profile
Firmenname
Uniqure N V
Sektor
Branche
Telefon
1-339-970-7000
Adresse
PAASHEUVELWEG 25A, AMSTERDAM
Compare QURE vs VRTX, REGN, ARGX, ALNY, ONC
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
QURE
Uniqure N V
|
10.65 | 563.12M | 16.10M | -198.97M | -183.99M | -3.4809 |
|
VRTX
Vertex Pharmaceuticals Inc
|
460.82 | 121.40B | 12.07B | 3.95B | 3.19B | 15.33 |
|
REGN
Regeneron Pharmaceuticals Inc
|
764.93 | 83.25B | 14.34B | 4.50B | 3.77B | 41.56 |
|
ARGX
Argen X Se Adr
|
728.11 | 46.39B | 4.16B | 1.29B | 734.26M | 19.59 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
320.51 | 43.41B | 3.71B | 313.75M | 465.38M | 2.2571 |
|
ONC
Beone Medicines Ltd Adr
|
292.94 | 33.09B | 5.36B | 287.73M | 924.18M | 2.5229 |
Uniqure N V Stock (QURE) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2026-01-28 | Eingeleitet | Barclays | Equal Weight |
| 2025-11-04 | Herabstufung | William Blair | Outperform → Mkt Perform |
| 2025-08-14 | Hochstufung | Mizuho | Neutral → Outperform |
| 2025-04-01 | Fortgesetzt | Chardan Capital Markets | Buy |
| 2024-12-10 | Hochstufung | Raymond James | Outperform → Strong Buy |
| 2024-10-10 | Fortgesetzt | Raymond James | Outperform |
| 2024-02-29 | Herabstufung | Goldman | Buy → Neutral |
| 2023-12-19 | Herabstufung | Mizuho | Buy → Neutral |
| 2022-03-17 | Hochstufung | UBS | Neutral → Buy |
| 2021-06-15 | Eingeleitet | BTIG Research | Buy |
| 2021-05-21 | Eingeleitet | UBS | Neutral |
| 2021-04-26 | Fortgesetzt | Credit Suisse | Outperform |
| 2021-04-01 | Hochstufung | Mizuho | Neutral → Buy |
| 2021-01-07 | Hochstufung | Guggenheim | Neutral → Buy |
| 2020-11-24 | Eingeleitet | H.C. Wainwright | Buy |
| 2020-11-11 | Eingeleitet | Berenberg | Buy |
| 2020-11-09 | Eingeleitet | Jefferies | Buy |
| 2020-11-04 | Eingeleitet | Cantor Fitzgerald | Overweight |
| 2020-10-23 | Eingeleitet | RBC Capital Mkts | Outperform |
| 2020-08-25 | Eingeleitet | Raymond James | Strong Buy |
| 2020-07-31 | Hochstufung | Robert W. Baird | Neutral → Outperform |
| 2020-06-25 | Herabstufung | Mizuho | Buy → Neutral |
| 2020-06-25 | Herabstufung | Robert W. Baird | Outperform → Neutral |
| 2020-06-25 | Herabstufung | Wells Fargo | Overweight → Equal Weight |
| 2019-12-03 | Eingeleitet | Cowen | Outperform |
| 2019-12-03 | Eingeleitet | Goldman | Buy |
| 2019-11-05 | Eingeleitet | Credit Suisse | Outperform |
| 2019-10-11 | Eingeleitet | Stifel | Buy |
| 2019-09-25 | Eingeleitet | Bernstein | Outperform |
| 2019-09-12 | Eingeleitet | Mizuho | Buy |
| 2019-07-30 | Herabstufung | Guggenheim | Buy → Neutral |
| 2019-07-08 | Bestätigt | Cantor Fitzgerald | Overweight |
| 2019-04-12 | Eingeleitet | Piper Jaffray | Overweight |
| 2019-03-29 | Eingeleitet | Robert W. Baird | Outperform |
Alle ansehen
Uniqure N V Aktie (QURE) Neueste Nachrichten
Is US FDA Following Correct Precedent With UniQure Gene Therapy Randomized Trial Demand? - Citeline News & Insights
uniQure used 'distorted comparison' in Huntington's asset trial: FDA official - Seeking Alpha
Kaplan Fox Encourages Investors of uniQure N.V. (QURE) to Contact the Firm Before Lead Plaintiff Deadline on April 13, 2026 - NewMediaWire
INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in uniQure N.V. of Class Action Lawsuit and Upcoming DeadlinesQURE - PR Newswire
Holzer & Holzer, LLC Reminds QURE Investors of the April - GlobeNewswire
Holzer & Holzer, LLC Reminds QURE Investors of the April 13, 2026 Lead Plaintiff Deadline in the uniQure N.V. Securities Class Action - GlobeNewswire Inc.
UniQure's Experimental Treatment for Huntington's Disease Faces Criticism From FDA Official - marketscreener.com
uniQure's (QURE) Gene Therapy for Huntington's Disease Faces FDA Setback - GuruFocus
FinancialContentKaplan Fox Encourages Investors of uniQure N.V. (QURE) to Contact the Firm Before Lead Plaintiff Deadline on April 13, 2026 - FinancialContent
uniQure (NASDAQ:QURE) Shares Up 12%Here's Why - MarketBeat
U.S. FDA official says uniQure is likely the latest company to make a failed therapy for Huntington's patients - marketscreener.com
US-listed shares of uniQure NV rise nearly 20% - marketscreener.com
uniQure N.V. (QURE) Class Action Lawsuit Seeks Recovery for Investors; April 13, 2026, DeadlineContact Kessler Topaz Meltzer & Check, LLP - FinancialContent
What's Going On With uniQure Stock On Thursday?uniQure (NASDAQ:QURE) - Benzinga
UniQure (QURE) Faces FDA Hurdle for Huntington's Disease Therapy - GuruFocus
FDA Push for Fake Brain Surgery Trial Spurs Ethical Concerns - Bloomberg.com
Portnoy Law Firm Announces Class Action on Behalf of uniQure N.V. Investors - GlobeNewswire
QURE CLASS ACTION NOTICE: Faruqi & Faruqi, LLP Reminds uniQure (QURE) Investors of Securities Class Action Deadline on April 13, 2026 - PR Newswire
UNIQURE N.V. (QURE) SHAREHOLDER ALERT Bernstein Liebhard LLP Reminds uniQure N.V. Investors of ... - Bluefield Daily Telegraph
UNIQURE N.V. (QURE) SHAREHOLDER ALERT Bernstein Liebhard - GlobeNewswire
The extremism of the FDA’s Marks and Prasad has come with costs - statnews.com
uniQure NV Hits Day Low of $15.51 Amid Price Pressure - Markets Mojo
QURE Investors Have Opportunity to Lead uniQure N.V. Securities Fraud Lawsuit with the Schall Law Firm - PR Newswire
uniQure NV Hits Day Low of $8.74 Amidst Intense Price Pressure - Markets Mojo
QURE Investors Have Opportunity to Lead uniQure N.V. Securities Fraud Lawsuit - Morningstar
uniQure NV Opens Weak with 12.86% Gap Down Amid Market Concerns - Markets Mojo
FDA official says UniQure fell short on Huntington's trial, defends new study request - Reuters
Why Did QURE Stock Almost Halve Pre-Market Today? - Stocktwits
ROSEN, A LONGSTANDING FIRM, Encourages uniQure N.V. Investors to Secure Counsel Before Important Deadline in Securities Class Action - GlobeNewswire Inc.
uniQure Shareholder Alert: ClaimsFiler Reminds Investors - GlobeNewswire
[144] uniQure N.V. SEC Filing - Stock Titan
uniQure (NASDAQ: QURE) RSUs vesting; insider sales of 12,378 and 34,437 - Stock Titan
Automatic tax-related share sale by uniQure (QURE) CEO Matthew Kapusta - Stock Titan
Tax-driven sale of 1,660 uniQure (QURE) shares by CMO - Stock Titan
uniQure Faces 2026 Shift to Dutch Large Company Regime, Curbing Direct Shareholder Control Over Board Appointments - The Globe and Mail
uniQure (QURE) Loses 67.5% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner - Finviz
What's Going On With uniQure Stock Wednesday? - Bitget
Berger Montague Reminds UniQure N.V. (QURE) Investors of Class Action Lawsuit Deadline - marketscreener.com
Investors who lost money on uniQure N.V.(QURE) should contact Levi & Korsinsky about pending Class ActionQURE - marketscreener.com
uniQure Faces Investor Lawsuit Over AMT-130 Trial Disclosures and Stock Drop - TipRanks
uniQure (QURE) Is Down 62.4% After AMT-130 Lawsuits Challenge Huntington’s Disclosure TimelineWhat's Changed - simplywall.st
uniQure: Worst Case Scenario Becomes Reality - Seeking Alpha
uniQure N.V. Securities Fraud Class Action Result of FDA - GlobeNewswire
uniQure N.V. Securities Fraud Class Action Result of FDA Approval Delay and 49% Stock Decline - GlobeNewswire Inc.
QURE INVESTOR ALERT: Bronstein, Gewirtz and Grossman, LLC Announces that uniQure N.V. Shareholders with Losses Have Opportunity to Lead Class Action Lawsuit! - ACCESS Newswire
UniQure N.V. (QURE): Wells Fargo Assigns Equal-Weight Rating With Price Target of $60 - 富途牛牛
Kaplan Fox Alerts Investors of uniQure N.V. (QURE) to a Securities Class Action Deadline on April 13, 2026 - FinancialContent
uniQure (QURE) Downgraded by Wells Fargo, Price Target Slashed | - GuruFocus
UniQure Shares Drop After Wells Fargo, Mizuho Downgrades - marketscreener.com
US FDA Commissioner Enters New Territory Hinting At UniQure Decision While Defending Prasad - Citeline News & Insights
Experts: Regulatory roadblocks stalling rare disease therapies - bioworld.com
Finanzdaten der Uniqure N V-Aktie (QURE)
Umsatz
Nettogewinn
Free Cashflow
ENV
3.69%
0.68%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):